New patent adds to NAI's already bulging CarnoSyn IP portfolio
Maintenance of these patents and adding to the support for its CarnoSyn branded form of beta alanine has formed a significant portion of NAI’s business strategy. NAI is also a major contract manufacturer counting the Juice Plus+ company and multilevel supplement marketing firm Mannatech among its primary clients. NAI now has 24 global patents in the US, Canada, China, Europe, Japan and Korea on CarnoSyn and its sustained release cousin. The new patent, US No. RE45,947, is titled "Methods and compositions for increasing the anaerobic working capacity in tissues."
Beta alanine has been a popular ingredient in sports nutrition formulations because of its role as a building block of carnosine, a molecule that can help buffer acid in the muscles and improve muscle performance and endurance. NAI says CarnoSyn is bolstered by 55 clinical studies which can be used to underpin eight health claims that include increased muscle strength, working capacity, and delayed fatigue.
NAI has a corporate history of vigorously defending the CarnoSyn IP portfolio and that won’t change, said CEO Mark LeDoux.
“This new patent is yet another example of NAI's ongoing commitment to the growth and protection of its CarnoSyn® beta-alanine patent portfolio. We will continue to pursue opportunities to expand our CarnoSyn® business around the world through vigorous research, development and enforcement of intellectual property,” he said.
